

Annual Report and Accounts

2019-20



www.sruk.co.uk

Charity Registration Number: 1161828

CONTENTS

Overview

Message from Chair and Chief Executive	3
Our Vision, Purpose & Values	4
Our Strategic Aims	4

Trustees' Report

What we did in 2019-20	
• Awareness	4
• Empowerment	5
• Healthcare	6
• Research	7
Financial Review	9
Principal Risks & Uncertainties	11
Structure, Governance & Management	11
Statement of Trustees' responsibilities	12

Independent Auditor's Report 14

Financial Statements

Consolidated Statement of Financial Activities	16
Consolidated and Charity Balance Sheets	17
Consolidated Cash Flow Statement	18
Notes to the Consolidated Financial Statements	19
Legal and Administrative Information	38

OVERVIEW

Message from Chair & Chief Executive

We have been working hard on our mission to minimise the impact of Scleroderma and Raynaud's on people's lives, until we ultimately find a cure. There are plenty of highlights to share from this year, none of which would have been possible without the amazing support of our community, clinicians and researchers.

Before SRUK launched in April 2016, we asked our community about their needs and the challenges they faced to identify what outcomes we needed to achieve. These outcomes have informed our strategy and the activities we undertake and in 2019, we ran a patient survey to evaluate our progress. The results, from over 1,000 people, were encouraging and demonstrate that the organisation is on the correct path towards achieving these outcomes.

The area where the organisation is having the most impact falls within our empowerment strategic aim, with 80% of respondents saying that SRUK helps them feel less alone, over 90% describing themselves as confident in discussing their condition, and with 67% giving the website a ranking of 5, on a scale of 1 to 5, where 5 is the most valuable.

The area where we need to do more work is in relation to our healthcare strategic aim, where our progress is very dependent on external stakeholders. To help us accelerate progress and achieve our objective of equitable access to treatments and care, we have continued to work in collaboration with other charities as part of the Rare Autoimmune Rheumatic Disease Alliance (RAIRDA). We met with senior officials at the National Institute for Health and Care Excellence to explore what options are available to help introduce Quality Standards for rare autoimmune conditions, to reduce unwarranted variations in care. While there are the British Society of Rheumatology's Best Practice Guidelines, these are not mandated. We had a very productive conversation, and we will continue to keep this dialogue going.


We know that finding a cure and increasing our investment in research is a key priority for our community and it is only through collaboration

that we will achieve our goals. In December 2019 we hosted a joint workshop with the World Scleroderma Foundation to look at how we can increase funding for Scleroderma research from key institutions and industry over the next 5 years.


Alongside awarding new research grants worth £98,959 co-funded with the World Scleroderma Foundation, we invested a further £312,638 on a range of projects looking at early diagnosis and improving the quality of data available on the conditions.

We continued our work to raise awareness about the signs and symptoms of both Scleroderma and Raynaud's. 80% of the media coverage promoted the charity with a link to the website, with sessions 50% up on the previous year. Our community play a vital role in helping to spread the word, through sharing their personal stories in the media and online and this year we reached a total of 160 Ambassadors.

We recognise that we are living in unprecedented times and that Covid-19 has created uncertainty and anxiety for many people in our community, so we are truly grateful for the continued generosity of our supporters.



Professor Jeremy Pearson
Chair of Trustees



Sue Farrington
Chief Executive

TRUSTEES' REPORT

Our Vision

A world where no-one has their life limited by Scleroderma and Raynaud's.

Our Purpose

Our mission is to improve the lives of everyone affected by Scleroderma and Raynaud's. We do this by investing in research, improving awareness and understanding of the conditions and providing information and support to all those affected.

Our Values

Our values inform how we deliver our services, the choices we make and how we work with, support and develop our staff and volunteers.

SRUK is:

Collaborative in the way we work.

Driven to see real change

Trusted because we are open and honest about the way we work.

Compassionate because we always put the person first.

Our Strategic Aims - 2017-2022

Awareness

Increase awareness of Scleroderma and Raynaud's with the public and health professionals.

Empowerment

Enable more people with Scleroderma and Raynaud's to manage their conditions through access to high quality information, support and guidance.

Healthcare

Ensure all people with Scleroderma and Raynaud's across the UK have access to high quality, integrated health and social care services, which are responsive to their needs.

Research

Ensure that research funded by SRUK translates into better prevention, diagnosis and treatment outcomes.

Infrastructure

Be an effective and efficient organisation, with the resources we need to achieve our goals.

SRUK's strategy 2017-2022 was informed and shaped by the challenges and needs of our community and provides us with a framework and clear direction of travel for our work. 2019-20 was the third year of delivery and we have reported below on the progress we have made during this period towards achieving our goals.

AWARENESS

Improving awareness and understanding of Scleroderma and Raynaud's is a key priority for SRUK. The focus for our media campaigns remains in increasing awareness and understanding of the signs and symptoms of these conditions with the public and professionals.

The condition of Raynaud's is poorly understood. It is not treated seriously by many professionals and consequently we do not know exactly how many people are affected or how severely it affects people. Raynaud's is to date the only known clinical condition considered to be a risk factor for developing Systemic Sclerosis or Scleroderma.

Lack of awareness has led to poor support and treatment of Raynaud's and delayed diagnosis of Scleroderma, which can have serious and life-threatening consequences.

In 2019-20 we:

- Developed a full media campaign, targeting TV, radio and print to increase awareness of the signs and symptoms of Scleroderma for Scleroderma Awareness Month in June

We secured 18 pieces of print and digital coverage, featuring in the Daily Mail, Daily Mirror, Metro, The Sun and regional press including the

TRUSTEES' REPORT

Yorkshire Post. We secured TV coverage on ITV Granada and Ulster TV featuring interviews with two of our members and we did live interviews with 25 radio stations, featuring a representative from SRUK and someone with Scleroderma who shared her own powerful story. In total our stories reached an audience of approximately 27 million people. 80% of the media coverage promoted the charity with a link to the website with sessions at 44,379, 50% up on the previous year.

Our community play a vital role in helping to spread the word, through sharing their personal stories in the media and online. This year to highlight the impact that Scleroderma can have, we asked our community to send us their #TenYearChallenge photos, showing how they had changed over the past decade.

We also published 4 videos throughout the month with members of our community sharing their experiences of being diagnosed, their first symptoms and what one thing they would like everyone to know about Scleroderma.

Our community told us that explaining their condition to family and friends was a challenge and so we produced a new 30 second animation for them to share with friends and family. The animation was viewed for 25,300 minutes in total and reached over 100,000 people.

- Collaborated with FESCA, the Federation of European Scleroderma Associations, to celebrate World Scleroderma Day to promote the 'Scleroderma will not take my smile: a whole world of support' campaign, using the #sclerosmile across our social media platforms. We had 38,000 impressions across our social media channels with 583 engagements on the day of June 29th alone.
- Continued with the established messages from previous awareness campaigns and promoted the online test for Raynaud's Awareness Month in February 2020. During the month 19,868 online tests were completed and there were over 72,657 visitors to our website. 94% of online and print media coverage had our name with a link to SRUK.

Whilst the breaking story of COVID-19 dominated the media we were able to secure national press coverage in The Times and I News, as well as several regional news pieces and a radio interview with our Head of Research on Radio Humberside.

We also secured several online articles with a blog on Bupa Online and Aspen Healthcare. The Bupa piece proved popular with their social media audience and had 198 shares - their usual average rate is between 20 and 50.

Our community distributed over 1,350 posters and information leaflets locally and we also had a double page spread in the Rowlands Pharmacy customer magazine that is distributed to 510 stores.

- Supported our community to share their personal stories, which are one of the most powerful and impactful ways to help other people more fully understand the nature of the condition and what it is like to live it. We are grateful to the increasing number of members from our community who have agreed to be Ambassadors, which now total 160 people.

EMPOWERMENT

Providing access to high quality, evidenced based information and support for people affected by Scleroderma and Raynaud's to help understand their condition and better manage their symptoms remains a core activity.

At the end of 2019-20, this became of vital importance as we responded to the challenges presented by the Covid-19 pandemic, which created huge anxiety and concern for many of our community who had to shield.

In 2019-20 we:

1. Worked quickly to respond and adapt our services to the growing need for information about the Coronavirus, gathering information relevant to the community and keeping the website updated, sometimes with daily updates in the early stages. We experienced a three-fold increase in enquiries to our helpline, main telephone line, our email info service and across

TRUSTEES' REPORT

all our social media platforms.

We developed regular digital features to keep the community engaged and talking to each other and saw an uplift in our social media engagement in the month of March with a 62% increase in impressions across all social media – from 52,000 to 85,000 and 150% increase in engagement from 3,700 to 9,500.

2. Continued to see growth in terms of reach and engagement across the year with a 31.5% increase in web users from 418,616 in 2018/19 to 549,850 in 2019-20. We saw growth across all our social media channels, where we provide support and information. Our Facebook community grew by 31% to 12,420, our Twitter community by 25% to 3,852 and our Instagram profile increased from 645 in 2018/19 to 1,199 an 83% growth. Our posts, ads and content were seen over 2,008,227 times.
3. Developed three new publications in line with the prioritisation exercise we conducted in 2017. These were Localised Scleroderma, Gastro & Intestinal Involvement and Lung Involvement & Pulmonary Arterial Hypertension. The aim is to ensure we have the most up to date, evidence-based information on all aspects of the condition. They were reviewed by our clinicians and patients in line with our best practice to meet quality standards for healthcare information.
4. Progressed our work to improve support offered to the community following the exercise we undertook in 2018/19 to better understand the needs of our diverse community, interviewing people living with the conditions and their loved ones. Overwhelmingly people wanted to be able to connect with other people and where possible face to face. So, during 2019/20 we been working on the development and growth of the support group network and we now have 12 Support Groups operating.
5. Following feedback from Members, this year we ran a couple of smaller conferences, rather than one big conference, to allow for greater geographical coverage throughout the year. The first took place in Cambridge on the 27th July attended by 63 people and the second was held

in Glasgow on the 12th October attended by 58 people. 90% of attendees rated their event good to excellent and 75% report workshops help them better self-manage.

6. Received over 1,000 calls to our Helpline, run by our dedicated team of volunteers living with the condition.

HEALTHCARE

We want to ensure that everyone with Scleroderma and Raynaud's, wherever they live and whatever their circumstances, gets the responsive and person-centred support they need. Key outcomes for SRUK are to ensure that there is equity of access to treatments and that care is properly co-ordinated in line with best practice guidelines

In 2019-20 we:

1. Participated in the National Institute for Health and Care Excellence (NICE), who launched a review of its methods for health technology evaluation in July 2019, designed to consider changes to the ways in which NICE makes decisions on which medicines, technologies and diagnostics the NHS should make routinely available to patients. While the scope of the review is wide-ranging, the methodology that NICE uses to assess treatments for rare and ultra-rare diseases will be a key area of focus.
As part of SRUK's contribution to the NICE methods and processes review for rare diseases we:
 - Called for the UK to make rare disease medicines available in the NHS as soon as they receive marketing authorisation through a period of managed access.
 - Collaborated with the SHCA on a position paper on the NICE methods review, setting out background to the review, key issues that need to be addressed and principles to guide reform.
 - Contributed to the published letter to The Editor of The Times, calling on NICE and NHS England to update their processes so people with rare and complex conditions have fair and

TRUSTEES' REPORT

- equal access to new drugs.
2. Participated in British Society of Rheumatology's Audit working group, looking at the implementation of best practice guidelines for Scleroderma. The group met in September 2019 to shape the questions for the audit. The audit was ready to go live in March 2020, but this has been postponed due to Covid-19.
 3. Continued to work in collaboration with the Rare Autoimmune Rheumatic Disease Alliance (RAIRDA) and in October 2019, the Chief Executive of SRUK was elected as the Co-Chair of RAIRDA. The Alliance developed a Policy Briefing paper to support conversations with MPs, Ministers and senior decision makers on the urgent need to focus on early diagnosis and improving co-ordination of care. The launch of the wider campaign was temporarily put on hold due to Covid-19, but we have continued to have conversations and gain the support from a wide range of MP's.
 4. Met with the Deputy Chief Executive of NICE and Dr Peter Lanyon, Co-Chair of RAIRDA to explore what options are available to help introduce Quality Standards for rare autoimmune conditions, as a way to help reduce unwarranted variations in care. While there are BSR Best Practice Guidelines, these are not mandated. The introduction of NICE Quality Standard's for Rheumatoid Arthritis has significantly improved levels of care for patients with the disease. Our aim is to achieve the same for patients in our community. We had a very productive conversation, and we are determined to keep this dialogue going.
 5. Continued to build our profile with other organisations, such as the Genetic Alliance and the General Medical Council (GMC), and SRUK's Chief Executive was invited to be part of GMC's Strategy Advisory Group. Alongside links in the UK, SRUK has strengthened links with other European and International organisations and agencies, including The European League Against Rheumatism (EULAR), The European Organisation for Rare Diseases (EURORDIS) and the World Scleroderma Foundation.

6. Participated in the 'national conversation' on rare diseases, launched by the Department of Health and Social Care (DHSC), to capture and understand the key current challenges facing the rare disease community across the UK, with the intention of using the responses to identify key themes for the overarching framework for rare diseases which the Department is developing to follow the UK Strategy on Rare Diseases.

RESEARCH

SRUK exists to ensure a world where no one has their lives limited by Scleroderma and Raynaud's, until we ultimately find a cure. A key core purpose of the organisation is to fund innovative and ground-breaking research so that our understanding of these conditions is translated into benefits for the community sooner rather than later.

To achieve our goal, we developed the organisation's first Research Strategy, working with patients, clinicians and industry. The scoping work led to the emergence of four key research themes: precision medicine, early detection, quality of life and understanding the cause.

Once the key research themes had been identified, it was important to understand what the challenges in accelerating these themes were. SRUK held a workshop with the researcher clinician community to identify the key challenges. Overall, four key challenges that represent significant blocks in accelerating the key research themes were identified:

- Lack of coherent and consistent datasets
- Few clinically validated molecular markers to enable diagnosis and stratification
- Lack of therapeutic intervention to address the condition as a whole
- Few objective outcome measures mean that assessing response to treatment and progression of the condition are difficult

To address the research gaps, as well as the challenges in accelerating these, the research strategy will seek to:

TRUSTEES' REPORT

- enable a strong foundation for research, which includes building a consistent dataset source and access to biomarkers
- promote collaboration between industry and academia
- ensure that wider scientific research into the conditions is supported and promoted
- produce a return on investment – both in terms of patient benefit and financial return to the organisation

To achieve our goals, SRUK is committed to working in partnership, to increase the capacity of the workforce and leverage resources from other institutions.

In 2019-20 we:

1. Held a successful three-day multidisciplinary workshop, 'Scleroderma Diagnosis Sandpit' at the end of February in London, supported by the Engineering and Physical Sciences Research Council (EPSRC), the main funding body for engineering and physical sciences research in the UK.

Twenty-four researchers from medicine, bioscience, engineering and data science came together to form new teams to find innovative approaches to the current challenges in treating Scleroderma. Several clinicians from the Scleroderma community participated. The goal of the event was to consider what non-invasive diagnostic tools could be developed with multi-disciplinary teams working together to develop a proof of concept for the diagnostic tool. Professor Christopher Denton attended the event and is on the final judging panel with Professor Ariane Herrick.

The final applications from the four teams are due to be submitted in 2020-21, when the judging panel will recommend which project should be awarded funding to develop a proof of concept model.

2. Held two successful meetings with clinicians and patients about the development of a Patient Registry. The first meeting was to explore the challenges and opportunities with a wider stakeholder group. There was

overwhelming support for the development of the Patient Registry. The follow up meeting was to establish a Steering group, which agreed several consensus points about the purpose and scope of the Registry as well as the initial set of data to be gathered.

3. Developed a Raynaud's App with Healthbit, which went live for the research participants involved in the Kennedy Cohort study led by Dr Francesco Del Galdo at Leeds University. The study will track 400 people with severe Raynaud's to see if and when they develop Scleroderma or other connective tissue diseases.
4. Continued to work with Insilico, in the form of a partnership between SRUK and the biotechnology company, supported by Professors Chris Denton and David Abraham. Insilico used artificial intelligence to identify possible drugs for re-purposing targeted at the fibrotic aspect of Scleroderma. They reported back on their findings and have identified 5 drugs for re-purposing and 2 novel compounds. We are now considering how we take this work forward.
5. Hosted a joint workshop with the World Scleroderma Foundation to look at how we can increase funding for Scleroderma research over the next 5 years from key institutions and industry.
6. Supported 8 on-going grants and awarded 2 new grants in partnership with World Scleroderma Foundation (WSF). The theme for the funding was Outcome Measures and the successful applicants were:
 - Dr Francesco Del Galdo; University of Leeds working with Dr Dinesh Khanna and Dr Dan Furst 'Validation of clinically and patient meaningful score values of ACR CRISS for diffuse cutaneous SSc.'
 - Dr Alain Lescoat, University Hospital of Rennes working with Dr Dinesh Khanna, University of Michigan: 'The CRISTAL Index: Developing a Combined Response Index for Scleroderma Trials Assessing Limited Cutaneous Systemic Sclerosis.'

TRUSTEES' REPORT

WHAT WE WILL DO IN 2020-21:

For our work in Awareness, we will:

Continue to deliver a series of public awareness campaigns around our two campaign peaks, the Scleroderma Awareness Campaign in June and Raynaud's Awareness Month in February.

Strengthen our network of journalists and build relationships with the medical and science press to maintain our position as the organisation for information and comment on matters relating to Scleroderma and Raynaud's.

Expand our network of patient ambassadors, supporting them to share their stories and act as ambassadors with local and regional media, to increase awareness about the conditions.

For our work in Empowerment, we will:

Respond to the ongoing need for up to date information about Covid-19 and produce appropriate content to support health and wellbeing.

Implement customer feedback mechanisms to measure the value and quality of our information.

Develop and grow our support group network to achieve coverage across the UK, utilising technology to support and connect people.

Continue to develop our social media networks for those affected by the conditions, based on insights into audience behaviours to identify content needed.

For our work in Healthcare we will:

Continue to work with the NHS and healthcare professionals to ensure information is available, particularly at point of diagnosis.

Continue our programme to establish SRUK presence in all clinics through key literature and visits.

Work with RAIRDA to drive forward the recommendations arising from the Patient Survey report with key organisations to ensure the voice of Scleroderma & Raynaud's is represented.

For our work in Research we will:

Continue to involve patients in our research programme to put their needs at the heart of the work we do.

Continue to implement the five-year research strategy to ensure we make the most effective use of the charity's limited resources.

Progress our work on a Raynaud's App to support research on early diagnosis and continue to explore the development of a Patient Registry.

FINANCIAL REVIEW

This report covers the period from 1st April 2019 to the 31 March 2020.

Overview

2019/20 has been a successful year for the Charity with fundraising income of £2,157,494 generating a surplus of £1,386,472 before investment and revaluation losses.

Our focus has continued to be to increase and diversify our fundraising and achieve a step change in our impact, effectiveness, and efficiency. We have continued the long-term approach towards financial planning and of investment in key areas.

We have also looked to invest significant amounts of our reserves into our work programme for the year to drive forward with our focus on improving impact and our reach to directly benefit people affected by Scleroderma and Raynaud's. This will continue into 2020/21.

How we raised our money

Key income streams for the charity comprise: Membership; Donations; Legacies; Trading and Fundraising Activities. In 2019-20 the total income for the group was £2,198,306.

We received £2,131,597 in donations and legacies; and £11,616 from membership, conference and other activities.

We are reporting a loss of £45,058 on our investments owing to the market turmoil at year-end as the Covid-19 crisis deepened.

TRUSTEES' REPORT

The value of investment holdings has since recovered.

The trading subsidiary of the charity brought in revenues of £40,811.

SRUK is registered with the Fundraising Regulator and is a member of the Institute of Fundraising. Our fundraising is carried out by a team of professional fundraisers based in our London headquarters, together with volunteers in their local communities. The team's activities are supervised by the Senior Management Team and follow recommended fundraising codes of practice. We did not receive any complaints about our fundraising activities in 2019-20.

How we spent our money

During 2019-20 our total charitable expenditure came to £645,068, an increase of £85,293 on the previous year.

This expenditure included £272,431 spent on Research (actually a total of £411,597 if the amounts relating to write backs of retracted grants are excluded). We also invested in the development of a range of services:

- Provision of information and support across all channels – print, online, phone and events. This included the development of the website and online platforms.
- Raising awareness of Scleroderma and Raynaud's with health care professionals and public.
- Establishing our campaigning & advocacy work through partnerships & alliances.
- Developing our infrastructure to ensure our organisation is efficient, effective and complies with all legal and regulatory requirements.

Balance Sheet

As at 31 March 2020, total funds were £3,224,893 for the Group and £3,227,371 for the Charity.

Reserves Policy

The Trustee Board has specified a reserves policy, which ensures that the Charity has sufficient funds to meet the cost of its day to day activities and is able to cope with the financial impact of unforeseen events. In addition, where possible funds should be set aside to meet future planned expenditure. These reserves are known as the Operating Reserve.

Operating Reserves

The charity should hold sufficient financial reserves to ensure it can continue to operate in the event of unforeseen and potentially financially damaging circumstances arising.

As the Covid-19 crisis began to escalate towards the end of the financial year the Board agreed that the reserves amount should be equivalent to a minimum of twelve months' operating expenditure, which would amount to operating reserves of £900,000 in the current year as against the current free reserves of the Group at £1,155,785 and Charity at £1,158,263. The Trustees believe therefore that the levels of reserves are adequate but not excessive.

Investment Policy

Rathbones Investment Management Limited continue as SRUK's investment managers. Over the year the value of these investments decreased to £488,947 due to the effect of the pandemic on the financial markets.

The investment manager reports on a quarterly basis on the performance of the investments under management. These reports are incorporated into the quarterly management accounts and the year-end accounts of the Charity and reviewed by the Trustees at the quarterly board meetings.

The Board of Trustees carries out an annual review of the investment principles under which the manager operates and hold an annual review of the performance of the portfolio with the investment manager.

TRUSTEES' REPORT

Grants Policy

Grants are accounted for fully in the year they are awarded in accordance with Charities SORP (FRS 102) requirements. They are therefore treated as liabilities in the accounts in the year they are awarded.

A number of underspends on historic research grants were written back at year end, to the value of £139,167.

Trading Subsidiary

Over 2019-20 SRUK's trading subsidiary brought in £40,811 of income.

£1,622 of staff costs were paid back to charity for the running of the shop, bringing total expenditure to £40,512. We continue to improve the technical and online capability of the shop as well as its operational efficiency and staff support costs. We expect the shop to continue to be modestly profitable.

Going Concern

After making appropriate enquiries, the trustees have a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. For this reason, they continue to adopt the going concern basis in preparing the financial statements.

Additional forecasting and reporting have been introduced since the beginning of the COVID-19 crisis, and the organisation has worked to understand and mitigate against additional risk where possible.

Principal Risks and Uncertainties:

SRUK is committed to effective risk management as an integral part of ensuring good corporate governance. Informed risk-taking helps to improve performance, manage our threats and opportunities and to create an environment of 'no surprises'. This will enable us to get the right balance between innovation and change.

We continue to develop, review and strengthen our risk management processes, enabling us to

conclude that major risks have been identified reviewed and where possible mitigated.

Key principal risks identified include the need for:

- Clear strategic direction
- Sufficient financial resources

To help mitigate these risks, SRUK has implemented various initiatives, including the development of a five-year strategy, based on key outcomes from the organisation's theory of change.

SRUK has an annual financial budget and operational plan aimed at managing financial risks and progressing the strategic plan. These are monitored on a quarterly basis by the Board.

A fundraising strategy outlines how SRUK will raise the money to meet its strategic goals.

Structure, governance and management

Scleroderma & Raynaud's UK (SRUK) is a Charitable Incorporated Organisation, registered charity number: 1161828

SRUK is governed by its Constitution.

The principal objects of the charity and the group are:

(i) to relieve persons suffering from Raynaud's and Scleroderma (Systemic Sclerosis), including the provision of financial support for such persons and their families in need;

(ii) to advance the education and awareness of the public and health professionals in all aspects of Raynaud's and scleroderma, including the provision and production of educational literature on these disorders; and

(iii) to provide financial support for research into the cause, treatment, care and prevention of both Raynaud's and Scleroderma and the dissemination of the results of such research for the public benefit.

TRUSTEES' REPORT

Method of appointment or election of Trustees

The management of the charity and the group is the responsibility of the Trustees who are elected and co-opted under the terms of the SRUK Constitution, registered with the Charity Commission on 26 May 2015.

Organisational structure and decision making

The trustees who served during the year are set out on page 38. The trustees have been selected for their expertise and professional skills. They meet quarterly with the Chief Executive.

Peer reviewers are invited to assist with the review of grant applications made to SRUK and their recommendations are reported back to the trustees who then approve or reject grant applications on merit or on the funding available. A Research sub-committee brings further rigour to the process.

Key Management Remuneration

SRUK is committed to a policy of equal pay and aims to ensure that salaries reflect the knowledge, skills, behaviours and capabilities required for satisfactory performance in each role whilst also demonstrating appropriate use of charitable donations. Salaries are benchmarked against the voluntary sector and where appropriate, other relevant job markets. Remuneration for key management personnel is handled in the same way as for all other staff.

Public Benefit

We have considered the Charity Commission's general guidance on public benefit when reviewing our aims and objectives and planning future activities. The Trustees always ensure that the activities undertaken are in line with the charitable objectives and aims of SRUK.

As highlighted in this report, some of our research grants are specifically targeted at trying to determine the cause of Scleroderma and Raynaud's, thereby helping the general population in finding better treatments in the future.

TRUSTEES' REPORT

STATEMENT OF TRUSTEES RESPONSIBILITIES AND CORPORATE GOVERNANCE

Trustees' responsibilities statement

The Trustees are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and regulations.

Company law requires the Trustees to prepare financial statements for each financial year and Trustees have elected to prepare the financial statements in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards and applicable law). Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and the group and of the incoming resources and application of resources, including the income and expenditure, of the charitable group for that period.

In preparing these financial statements, the Trustees are required to:

- Select the most suitable accounting policies and then apply them consistently.
- Observe the methods and principles in the Charity SORP.
- Make judgments and accounting estimates that are reasonable and prudent.
- State whether applicable UK Accounting Standards have been followed, subject to any material departures disclosed and explained in the financial statements.
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable group will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain the charitable company's transactions and disclose with reasonable accuracy at any time the financial position of the company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets

of the charitable company and the group and ensuring their proper application under charity law and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as each of the Trustees is aware:

- there is no relevant audit information of which the charitable company's auditor are unaware
- the Trustees have each taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditors are aware of that information.

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

This report was approved by the Board of Trustees on 10 December 2020 and signed on their behalf by:



Chris Coombe, Treasurer

Independent auditor's report to the trustees of SRUK

INDEPENDENT AUDITOR'S REPORT TO THE TRUSTEES OF SRUK

Opinion

We have audited the financial statements of Scleroderma & Raynaud's UK for the year ended 31 March 2020 which comprise the Consolidated Statement of Financial Activities, the Consolidated Balance Sheet, the Charity Balance Sheet, the Consolidated Statement of Cash Flows and notes to the financial statements, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion, the financial statements:

- give a true and fair view of the state of the group's and of the parent charity's affairs as at 31 March 2020 and of the group's net movement in funds for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Charities Act 2011.

Basis for opinion

We have been appointed as auditor under section 144 of the Charities Act 2011 and report in accordance with the Act and relevant regulations made or having effect thereunder. We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of trustees for the financial statements

As explained more fully in the trustees' responsibilities statement set out on page 16, the trustees are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the trustees are responsible for assessing the group's and the parent charity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustees either intend to liquidate the group or the parent charity or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the financial statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

Conclusions relating to going concern

We have nothing to report in respect of the following matters in relation to which the ISAs

INDEPENDENT AUDITOR'S REPORT TO THE TRUSTEES OF SRUK

(UK) require us to report to you where:

- the trustees' use of the going concern basis of accounting in the preparation of the financial statements is not appropriate; or
 - the trustees have not disclosed in the financial statements any identified material uncertainties that may cast significant doubt about the group's or the parent charity's ability to continue to adopt the going concern basis of accounting for a period of at least twelve months from the date when the financial statements are authorised for issue.
- adequate accounting records have not been kept by the parent charity; or
 - sufficient accounting records have not been kept; or
 - the parent charity financial statements are not in agreement with the accounting records and returns; or
 - we have not received all the information and explanations we require for our audit.

Other information

The trustees are responsible for the other information. The other information comprises the information included in the Trustees' Annual Report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.


In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether there is a material misstatement in the financial statements or a material misstatement of the other information. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Matters on which we are required to report by exception

We have nothing to report in respect of the following matters in relation to which the Charities (Accounts and Reports) Regulations 2008 require us to report to you if, in our opinion:

Use of our report

This report is made solely to the charity's trustees, as a body, in accordance with section 144 of the Charities Act 2011 and regulations made under section 154 of that Act. Our audit work has been undertaken so that we might state to the charity's trustees those matters we are required to state to them in an Auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charity's trustees as a body for our audit work, for this report, or for the opinions we have formed.



Haysmacintyre LLP
Statutory Auditors
10 Queen Street Place
London EC4R 1AG

Haysmacintyre LLP is eligible to act as an auditor in terms of section 1212 of the Companies Act 2006

SCLERODERMA & RAYNAUD'S UK
CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES
(INCORPORATING AN INCOME AND EXPENDITURE ACCOUNT)
FOR THE YEAR ENDED 31 MARCH 2019

INCOME FROM:	Notes	Total Funds 2020	Total Funds 2019
		£	£
Donations and legacies	5	2,131,597	521,961
Investments	7	14,282	11,241
Membership and conferences	6	5,713	8,182
Other	8	5,903	-
Total fundraising income		2,157,495	541,384
EXPENDITURE ON:			
Raising funds: donations and legacies	10	(126,254)	(142,843)
Total fundraising expenditure		(126,254)	(142,843)
Fundraising Contribution		2,031,241	398,541
Trading income	9	40,811	46,388
Trading expenditure	9	(40,512)	(43,804)
Contribution from trading activities		299	2,584
Net income available for charitable purposes		2,031,540	401,125
Charitable expenditure			
Research	10	(272,430)	(232,496)
Services to members	10	(372,638)	(327,279)
Total charitable expenditure		(645,068)	(559,775)
Net income/(expenditure) before (loss)/gain on investments		1,386,472	(158,650)
Represented by			
Total income		2,198,306	587,773
Total expenditure	10	(811,834)	(746,423)
Net income/(expenditure) before (loss)/gain on investments		1,386,472	(158,650)
Net (loss)/gain on investments	15	(45,058)	7,082
Net income/(expenditure)		1,341,414	(151,568)
Other recognized (losses)/gains			
Net (loss) on property revaluation	14	(20,000)	-
Net movement in funds		1,321,414	(151,568)
Reconciliation of funds			
Fund balances brought forward		1,903,479	2,055,047
Total funds carried forward	21	3,224,893	1,903,479

SCLERODERMA & RAYNAUD'S UK

BALANCE SHEET

AS AT 31 MARCH 2020

FIXED ASSETS	Notes	Group 2020 £	Group 2019 £	Charity 2020 £	Charity 2019 £
Tangible assets	14	-	150,231	-	150,231
Investments	15	488,947	525,259	488,947	525,259
		488,947	675,490	488,947	675,490
CURRENT ASSETS					
Current asset held for resale	17	130,000	-	130,000	-
Stock	16	11,067	22,166	-	-
Debtors: amounts falling due within one year	18	1,611,363	169,268	1,648,937	194,564
Cash at bank and in hand		1,449,229	1,594,017	1,423,487	1,579,495
		3,201,659	1,785,451	3,202,424	1,774,059
CREDITORS:					
amounts falling due within one year	19	(465,713)	(557,462)	(464,000)	(543,462)
NET CURRENT ASSETS		2,735,946	1,227,989	2,738,424	1,230,597
Total assets less current liabilities		3,224,893	1,903,479	3,227,371	1,906,087
NET ASSETS		3,224,893	1,903,479	3,227,371	1,906,087
CAPITAL AND RESERVES					
Designated funds	20 & 21	2,069,108	1,308,722	2,069,108	1,308,722
Unrestricted funds	20 & 21	1,155,785	594,757	1,158,263	597,365
		3,224,893	1,903,479	3,227,371	1,906,087

These financial statements were approved and authorised for issue by the Board on the 21st January 2020 and are signed on their behalf by C Coombe



Chris Coombe, Treasurer

SCLERODERMA & RAYNAUD'S UK CONSOLIDATED CASH FLOW STATEMENT FOR THE YEAR ENDED 31 MARCH 2020

Cash flows from operating activities	2020	2020	2019	2019
	£	£	£	£
Net income/(expenditure) for the year (as per the Consolidated Statement of Financial Activities)	1,321,414		(151,568)	
Adjustments for:				
Current asset held for resale				
Depreciation charges	231		232	
Impairment of fixed assets	20,000		-	
Dividends, interest and rents from investments	14,282		(11,241)	
Decrease/(increase) in stocks	11,099		(12,463)	
(Increase)/decrease in debtors	(1,442,094)		1,006,479	
Decrease in creditors	(91,749)		117,053)	
Net cash provided by / (used in) operating activities		(195,381)		714,386
Cash flows from investing activities				
Dividends, interest and rents from investments	14,282		11,241	
Purchase of investments	(193,210)		(57,200)	
Sale of investments	184,463		50,813	
(Losses)/gains on investments	45,058		(7,082)	
Net cash (used in) / provided by investing activities		50,593		(2,228)
Change in cash and cash equivalents in the year		(144,788)		712,158
Cash and cash equivalents at the beginning of the year		1,594,017		881,859
Cash and cash equivalents at the end of the year		1,449,229		1,594,017

SCLERODERMA & RAYNAUD'S UK

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2020

1. GENERAL INFORMATION

Scleroderma & Raynaud's UK ('the Charity' or 'SRUK') and its subsidiary (together "the Group") support the research of Raynaud's and Scleroderma diseases and offer advice and support to individuals suffering from the conditions throughout the UK.

Scleroderma & Raynaud's UK is a public benefit entity having registered charity number 1161828 and was incorporated in England. The address of its registered office is Bride House, 18-20 Bride Lane, London, EC4Y 8EE.

2. ACCOUNTING POLICIES

a) Basis of Preparation of Financial Statements

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) effective 1 January 2019) - (the Statement of Recommended Practice for Charities (SORP 2015) (Second Edition, effective 1 January 2019)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Charities Act 2011.

The SRUK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The statement of financial activities (SOFA) and balance sheet consolidate the financial statements of the Charity and its subsidiary undertaking being RSA Trading Company Limited. The results of the subsidiary are consolidated on a line by line basis after the elimination of intra-group transactions. Control has been obtained by the ownership of shares.

b) Going concern

The trustees have assessed whether the use of the going concern assumption is appropriate in preparing these financial statements. The trustees have made this assessment in respect to a period of one year from the date of approval of these financial statements and have considered the impact of the coronavirus pandemic on the charity's operations. In particular the trustees have

considered the charities forecasts and projections and have taken account of pressures on donation income. After making enquiries the trustees have concluded there is a degree of uncertainty around donation income for 2020/21 however that there is a reasonable expectation that the charity has adequate resources to continue in operational existence for the foreseeable future. The Trustees confirm that there are no material uncertainties about the ability of the charity to continue as a going concern. The charity therefore continues to adopt the going concern basis in preparing its financial statements.

c) Fund Accounting

General funds are unrestricted funds which are available for use at the discretion of the Trustees in furtherance of the general objectives of the charity and which have not been designated for other purposes.

Designated funds are unrestricted funds earmarked by the Trustees for particular purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the charity for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

d) Income

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably. For legacies, entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted, the estate has been finalised and notification has been made by the executor(s) to the Trust that a distribution will be made, or when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution.

Where legacies have been notified to the charity, or the charity is aware of the granting of probate, and the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material.

Donated services or facilities are recognised when the charity has control over the item, any

SCLERODERMA & RAYNAUD'S UK

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2020

conditions associated with the donated item have been met, the receipt of economic benefit from the use of the charity of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102). The general volunteer time of the friends is not recognised and refer to the Trustees' Report for more information about their contribution.

On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the charity which is the amount the charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

Income tax recoverable in relation to investment income is recognised at the time the investment income is receivable.

e) Expenditure

Expenditure is recognised once there is a legal or constructive obligation to transfer economic benefit to a third party, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably.

Expenditure is classified under the principal categories of charitable and other expenditure rather than the type of expense, in order to provide more useful information to users of the accounts.

Cost of raising funds are those incurred in seeking voluntary contributions, and those incurred in trading activities that raise funds but do not include the costs of disseminating information in support of the charitable activities.

Charitable activities comprise direct expenditure including direct staff costs attributable to the activity.

Support costs are those costs incurred directly in support of expenditure on the objects of the charity and include project management.

Governance costs are those incurred in connection with the management of SRUK's assets, organisational administration and compliance with constitutional and statutory requirements.

Support and Governance costs are allocated on the basis of time spent on each activity.

Grants are accounted for fully in the year they are awarded in accordance with Charities SORP (FRS 102) requirements. They are therefore treated as liabilities in the accounts in the year they are awarded, where they have not been paid at the year end.

f) Tangible Fixed Assets

All assets costing more than £1,000 are capitalised.

Tangible fixed assets are carried at cost or valuation, net of depreciation and any provision for impairment. Depreciation is not charged on freehold land. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

Office equipment 20% straight line

g) Revaluation of tangible fixed assets

The charity has adopted the cost model whereby items of property, plant and equipment are measured at cost less any accumulated depreciation and any accumulated impairment losses.

h) Building held for sale

The property held for sale is held in the accounts at fair value. The asset has been impaired in the year and the building has been sold to a third party since the year end.

i) Investments

Fixed asset investments are a form of financial instrument and are initially recognised at their transaction cost and subsequently measured at fair value at the Balance Sheet date, unless fair value cannot be measured reliably in which case it is measured at cost less impairment. Investment gains and losses, whether realised or unrealised, are combined and shown in the heading 'Gains/(losses) on investments' in the Statement of Financial Activities.

Subsidiary undertakings:

Investments in subsidiaries are valued at cost less provision for impairment.

j) Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the Bank.

SCLERODERMA & RAYNAUD'S UK

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2020

k) Stocks

Stocks are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads.

l) Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered.

Prepayments are valued at the amount prepaid net of any trade discounts due.

m) Cash and cash equivalents

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

n) Liabilities and provisions

Liabilities are recognised when there is an obligation at the Balance Sheet date as a result of a past event, it is probable that a transfer of economic benefit will be required in settlement, and the amount of the settlement can be estimated reliably. Liabilities are recognised at the amount that the charity anticipates it will pay to settle the debt or the amount it has received as advanced payments for the goods or services it must provide. Provisions are measured at the best estimate of the amounts required to settle the obligation. Where the effect of the time value of money is material, the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that reflects the risks specific to the liability. The unwinding of the discount is recognised within interest payable and similar charges.

o) Financial Instruments

The Charity only enters into basic financial instruments transactions that result in the recognition of financial assets and liabilities like trade and other debtors and creditors, loans from banks and other third parties, loans to related parties and investments in non-puttable ordinary shares.

Debt instruments (other than those wholly repayable or receivable within one year), including loans and other accounts receivable and payable, are initially measured at present value of the future cash flows and subsequently at amortised cost using the effective interest method. Debt instruments that are payable or receivable within

one year, typically trade payables or receivables, are measured, initially and subsequently, at the undiscounted amount of the cash or other consideration expected to be paid or received. However if the arrangements of a short-term instrument constitute a financing transaction, like the payment of a trade debt deferred beyond normal business terms or financed at a rate of interest that is not a market rate or in case of an out-right short-term loan not at market rate, the financial asset or liability is measured, initially, at the present value of the future cash flow discounted at a market rate of interest for a similar debt instrument and subsequently at amortised cost.

Financial assets that are measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the profit and loss account.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between an asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If a financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between an asset's carrying amount and best estimate, which is an approximation of the amount that the Charity would receive for the asset if it were to be sold at the balance sheet date.

Financial assets and liabilities are offset and the net amount reported in the Balance Sheet when there is an enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

p) Taxation

The charity is exempt from tax on its charitable activities.

q) Termination benefits

Settlement agreements are recognised in the period they are incurred.

SCLERODERMA & RAYNAUD'S UK

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2020

3. JUDGEMENTS IN APPLYING ACCOUNTING POLICIES AND KEY SOURCES OF ESTIMATION UNCERTAINTY

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Critical accounting estimates and assumptions:

The charity makes estimates and assumptions concerning the future. The resulting accounting estimates and assumptions will, by definition, seldom equal the related actual results. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

Critical areas of judgement:

(i) Useful economic lives of tangible assets

The annual depreciation charge for tangible assets is sensitive to changes in the estimated useful economic lives and residual values of the assets. The useful economic lives and residual values are

re-assessed annually. They are amended when necessary to reflect current estimates, based on technological advancement, future investments, economic utilisation and the physical condition of the assets. See note 14 for the carrying amount of the tangible fixed assets and note 2(f) for the useful economic lives for each class of assets.

(ii) Impairment of fixed assets

At regular intervals, and at least annually, management review the carrying value of tangible fixed assets to determine whether this fairly represents the recoverable amount from their use. The carrying value is compared to the recoverable amount, defined as the higher of:

- Value in use is calculated from expected earnings streams or savings from continued employment of the asset
- Realisable value on a disposal

(iii) Accrued grants payable

Using the accruals basis of accounting, grants payable are matched to the period or are reported when the expense occurs, not when the cash is paid.

4. JUDGEMENT INCOME/(EXPENDITURE) FOR THE YEAR

Net expenditure for the year is stated after charging:

	Group		Charity	
	2020	2019	2020	2019
	£	£	£	£
Depreciation on owned assets	231	232	231	232
Auditor's remuneration	8,900	8,350	8,900	8,350

5. DONATIONS AND LEGACIES

Group & Charity:

	Total Funds 2020	Total Funds 2019
	£	£
Donations	387,226	320,729
Legacies	1,744,371	201,232
	2,131,597	521,961

SCLERODERMA & RAYNAUD'S UK

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2020

6. MEMBERSHIP AND CONFERENCE INCOME

Group & Charity:	Total Funds 2020 £	Total Funds 2019 £
Membership income	5,686	7,403
Conference income	27	779
	5,713	8,182

7. INVESTMENT INCOME

Group & Charity:	Total Funds 2020 £	Total Funds 2019 £
Dividend income	12,186	7,069
Interest income	2,096	4,172
	14,282	11,241

8. OTHER INCOME

Group & Charity:	Total Funds 2020 £	Total Funds 2019 £
Other	5,903	-
	5,903	-

9. TRADING ACTIVITIES

Group	Income/ Direct Costs 2020 £	Support Cost Allocation 2020 £	Total 2020 £	Total 2019 £
Trading income	40,811	-	40,811	46,388
Trading costs	(40,512)	-	(40,512)	(43,804)
Trading net profit/(loss)	299	-	299	2,584
Contribution from trading activities	299	-	299	2,584

All trading activities income received in the year were unrestricted.

SCLERODERMA & RAYNAUD'S UK

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2020

10. EXPENDITURE 2020

Group	Grants £ (note 11)	Staff Costs £	Other Direct Costs £	Support Cost Allocations £ (note 12)	Total 2020 £
Expenditure on Raising Funds					
Cost of Raising Funds	-	53,086	50,027	23,141	126,254
Expenditure on Trading Activities					
Retail (100% trading sub)	-	1,622	38,890	-	40,512
Expenditure on Charitable Activities					
Research	(40,208)	79,634	195,009	37,995	272,430
Services to Members	-	195,203	84,298	93,137	372,638
Support Costs Allocated	-	30,516	123,757	(154,273)	-
Total Expenditure	(40,208)	360,061	491,981	-	811,834

Prior Year

Group	Grants £ (note 11)	Staff Costs £	Other Direct Costs £	Support Cost Allocations £ (note 12)	Total 2020 £
Expenditure on Raising Funds					
Cost of Raising Funds	-	67,009	49,420	26,414	142,843
Expenditure on Trading Activities					
Retail (100% trading sub)	-	5,136	38,668	-	43,804
Expenditure on Charitable Activities					
Research	141,278	65,588	-	25,630	232,496
Services to Members	-	160,698	103,781	62,800	327,279
Support Costs Allocated	-	28,587	86,257	(114,844)	-
Total Expenditure	141,278	327,018	278,126	-	746,422

SCLERODERMA & RAYNAUD'S UK

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2020

11. GRANTS

Analysis of grant expenditure	2020	2019
	£	£
Group & Charity:		
University College London	-	128,312
Alder Hay	-	13,610
Universities of Rennes and Michigan	50,000	-
University of Leeds	48,959	-
Write backs	(139,167)	(644)
	(40,208)	141,278

Of the total grants payable £98,959 relates to grants payable to institutions (2019: £141,922). During the year a number of grants were confirmed as completed and the outstanding balances were written back.

Grant commitments are as follows:	2020	2019
	£	£
Group & Charity		
Grant commitments at 1 April	391,779	620,145
Awards made during year	98,959	141,922
Payments made during the year	(28,199)	(369,644)
Grants retracted	(139,167)	(644)
	323,372	391,779

12. GOVERNANCE AND SUPPORT COSTS

Group & Charity:	2020	2019
	£	£
Support & Governance:		
Support staff costs	23,843	23,132
Human resources	6,356	3,877
Facilities	40,618	17,905
Finance & legal	30,336	29,009
Office costs	34,051	22,663
Governance staff costs	6,672	5,455
Governance other costs	12,397	12,803
Total support and governance costs	154,273	114,844

SCLERODERMA & RAYNAUD'S UK

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2020

13. STAFF COSTS

Staff costs were as follows:	Group		Charity	
	2020 £	2020 £	2020 £	2019 £
Wages and salaries	297,739	289,682	296,117	284,546
Social security costs	27,548	25,381	27,548	25,381
Pension	6,446	3,928	6,445	3,928
Temporary staff	28,328	8,027	28,327	8,027
	360,061	327,018	358,438	321,882

The average number of employees during the year was as follows:

	2020	2019
	No.	No.
Staff	9	9

Employees receiving remuneration amounting to more than £60,000 were as follows:

	2020	2019
Remuneration	No.	No.
£70,000 - £79,999	1	1

During the year there were no redundancies and in the prior year redundancy was paid to one employee £nil (2019: £2,436).

The key management personnel of the charity comprise the trustees and the senior management team as listed on page 38. The total amount of employee benefits (including employer pension contributions) received by key management personnel for their services to SRUK was £148,802 (2019: £140,776).

TRUSTEES

None of the trustees (or any person connected with them) received any remuneration during the current or preceding year, and total expenses reimbursed to trustees was £1,664 relating to three trustees for traveling and other expenses (2019 - £1,263 for 4 trustees).

SCLERODERMA & RAYNAUD'S UK NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2020

14. FIXED ASSETS

Group & Charity:	Freehold land and buildings £	Furniture and equipment £	Total £
Cost			
At 1 April 2019	150,000	1,159	151,159
Impairment	(20,000)	-	(20,000)
Transfer to asset held for resale	(130,000)	-	(130,000)
At 31 March 2020	-	1,159	1,159
Depreciation			
At 1 April 2019	-	928	928
Depreciation charge	-	231	231
At 31 March 2020	-	1,159	1,159
Net Book Value			
At 31 March 2019	150,000	231	150,231
At 31 March 2020	-	-	-

Advice was taken from local estate agents as to the appropriate values for the freehold land and buildings intended for sale.

SCLERODERMA & RAYNAUD'S UK

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2020

15. FIXED ASSET INVESTMENTS

Group & Charity:	2020 Total £	2019 Total £
Investments		
Market value of quoted investments at 1 April 2019	499,962	487,813
Additions	193,209	57,200
Disposal proceeds	(205,348)	(52,133)
Net investment (loss)/gain	(45,058)	7,082
Market value of quoted investments at 31 March 2020	442,765	499,962
Cash on deposit	46,182	25,297
Market value at 31 March 2020	488,947	525,259
Historic cost at 31 March 2020	524,756	519,658
Accumulated unrealised (loss)/gain	(35,808)	5,601
Historic Cost Gains		
Net investment (loss)/gain	(45,058)	7,082
Movement on unrealised (loss) / gain	42,170	(4,049)
Realised (losses)/gains based on historic cost	(2,888)	3,033

All the fixed asset investments are held in the UK.
Investments have been valued at market value at the balance sheet date.

Investments are represented by:	2020 Total £	2019 Total £
Cash	46,182	25,297
Equity	146,616	135,258
Fixed interest	113,465	159,038
Alternatives	71,207	66,845
Overseas	111,477	138,821
Total	488,947	525,259

SCLERODERMA & RAYNAUD'S UK

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2020

16. STOCK

	Group		Charity	
	2020 £	2019 £	2020 £	2019 £
Stock	11,067	22,166	-	-

17. CURRENT ASSET HELD FOR RESALE

	Group		Charity	
	2020 £	2019 £	2020 £	2019 £
Freehold land and building	130,000	-	130,000	-

Advice was taken from local estate agents as to the appropriate values for the freehold land and buildings intended for sale. The asset has since been sold at the year-end value of £130,000.

18. DEBTORS

	Group		Charity	
	2020 £	2019 £	2020 £	2019 £
Due within one year				
Trade debtors	70,143	8,500	62,000	885
Amounts owed by group entities	-	-	48,406	46,940
Accrued income	1,519,943	136,085	1,519,943	136,085
Other debtors	2,729	16,208	48	2,188
Prepayments	18,548	8,475	18,540	8,466
	1,611,363	169,268	1,648,937	194,564

19. CREDITORS

	Group		Charity	
	2020 £	2019 £	2020 £	2019 £
Trade creditors	93,721	130,394	111,091	128,738
Deferred income	8,264	-	8,264	-
Other creditors	1,132	-	1,132	-
Taxes and social security	8,466	7,726	8,346	5,445
Accruals	30,758	27,563	11,795	17,500
Grant commitments	323,372	391,779	323,372	391,779
	465,713	557,462	464,000	543,462

SCLERODERMA & RAYNAUD'S UK

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2020

DEFERRED INCOME:

Group and Charity

	2020 £	2019 £
Opening balance	-	1,897
Income released in the year	-	(1,897)
Income deferred in the year	<u>8,264</u>	<u>-</u>
Closing balance	<u>30,758</u>	<u>-</u>

Deferred income relates to deferred membership subscriptions.

20. UNRESTRICTED FUNDS

GROUP	Funds brought forward £	Income £	Expenditure including gains and losses £	Transfer £	Funds carried forward £
Designated	1,308,722	-	(239,614)	1,000,000	2,069,108
General	486,391	2,198,306	(637,278)	(1,000,000)	1,047,419
Revaluation	108,366	-	-	-	108,366
	<u>1,903,479</u>	<u>2,198,306</u>	<u>(876,892)</u>	<u>-</u>	<u>3,224,893</u>

CHARITY

Designated	1,308,722	-	(239,614)	1,000,000	2,069,108
General	488,999	2,157,495	(596,597)	(1,000,000)	1,049,897
Revaluation	108,366	-	-	-	108,366
	<u>1,906,087</u>	<u>2,157,495</u>	<u>(836,211)</u>	<u>-</u>	<u>3,227,371</u>

Prior Year

GROUP	Funds brought forward £	Income £	Expenditure including gains and losses £	Transfer £	Funds carried forward £
Designated	1,450,000	-	(141,278)	-	1,308,722
General	496,681	587,772	(598,062)	-	486,391
Revaluation	108,366	-	-	-	108,366
	<u>2,055,047</u>	<u>587,772</u>	<u>(739,340)</u>	<u>-</u>	<u>1,903,479</u>

SCLERODERMA & RAYNAUD'S UK

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2020

CHARITY	Funds brought forward £	Income £	Expenditure including gains and losses £	Transfer £	Funds carried forward £
Designated	1,450,000	-	(141,278)	-	1,308,722
General	502,031	546,363	(559,395)	-	488,999
Revaluation	108,366	-	-	-	108,366
	2,060,397	546,363	(700,673)	-	1,906,087

Additional funds designated in the current year:

- Designated fund of £800,000 into research over 5 years.
- Designated fund of £200,000 to pump prime projects over the next 3 years to raise even more funds for our work and for development of the strategic themes of awareness, empowerment and healthcare.

21. ANALYSIS OF NET ASSETS

GROUP	Unrestricted £	Designated £	Restricted £	Total £
Trade creditors	-	-	-	-
Tangible fixed assets	-	-	-	-
Investments	488,947	-	-	488,947
Current assets	1,132,551	2,069,108	-	3,201,659
Current liabilities	(465,713)	-	-	(465,713)
	1,155,785	2,069,108	-	3,224,893

CHARITY	Unrestricted	Designated	Restricted	Total
Tangible fixed assets	-	-	-	-
Investments	488,947	-	-	488,947
Current assets	1,133,316	2,069,108	-	3,202,425
Current liabilities	(464,000)	-	-	(464,000)
	1,158,263	2,069,108	-	3,227,371

Prior Year

GROUP	Unrestricted	Designated	Restricted	Total
Tangible fixed assets	150,231	-	-	150,231
Investments	525,259	-	-	525,259
Current assets	476,729	1,308,722	-	1,785,451
Current liabilities	(557,462)	-	-	(557,462)
	594,757	1,308,722	-	1,903,479

SCLERODERMA & RAYNAUD'S UK NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 MARCH 2020

CHARITY	Unrestricted	Designated	Restricted	Total
Tangible fixed assets	150,231	-	-	150,231
Investments	525,259	-	-	525,259
Current assets	465,337	1,308,722	-	1,774,059
Current liabilities	(543,462)	-	-	(543,462)
	<u>597,365</u>	<u>1,308,722</u>	<u>-</u>	<u>1,906,087</u>

22. RELATED PARTIES

During the year staff recharges of £1,622 (2019 - £5,136) were made to RSA Trading Company Limited; as at 31 March 2020 SRUK are due £48,406 (2019 - £46,940) from RSA Trading Company Limited.

All transactions were carried out at arm's length.

23. PRINCIPAL SUBSIDIARIES

Company Name	Country	Percentage	Description
RSA Trading Company Limited	United Kingdom	100%	Sale of products to help with the medical conditions of Raynaud's and Scleroderma

The subsidiary was registered in England and Wales with registered number 07869668.

Financial review:

	2020 £	2019 £
Net assets	(2,462)	(2,761)
Income	40,811	46,388
Expenditure	(40,512)	(43,804)
Profit	<u>299</u>	<u>2,584</u>

SCLERODERMA & RAYNAUD'S UK

NOTES TO THE FINANCIAL STATEMENTS

FOR THE YEAR ENDED 31 MARCH 2020

24. OPERATING LEASES

Group and Charity Operating Leases – Buildings	2020 £	2019 £
Amounts due:		
< 1 year	8,064	8,064
2-5 years	6,084	14,112
>5 years	-	-
Total	14,112	22,176

25. POST BALANCE SHEET EVENTS

The accounts have been approved during a period where there is much uncertainty as a result of the emergence and international spread of a coronavirus (COVID-19). The trustees consider that this is a non-adjusting post balance sheet event because the impact on the charity in 2020/21 has been significant but no adjustments are required to these financial statements as a result of the matter identified.

Since the year end the charity has been notified of a pecuniary legacy of £1,000,000. Since the date of notification fell in July 2020, after the balance sheet date, this is a non-adjusting post balance sheet event.

WHO WE ARE:

Trustees:

Christopher Coombe
Kenneth Hicks
Susan Hoare
Professor Jeremy Pearson
Helena Rozga
Professor David G.I. Scott
Jitinder Saini (Appointed 27th July 2020)
Jason Bryant (Appointed 6th November 2020)

Chief Executive Officer:

Sue Farrington

Senior Management Team:

David Atkinson, Gemma Cornwell, Emma Blamont

Principal Bankers:

NatWest Bank
1 Upper Market Square, Hanley
Stoke on Trent
ST11NS

CAF Bank Limited,
25 Kings Hill Avenue, Kings Hill
West Malling, Kent
ME19 4JQ

Solicitors:

DLA Piper
3 Noble Street
London
EC2V 7EE

Clyde & Co
Beaufort House
15 St Botolph St
Spitalfields
London EC3A 7NJ

Auditors:

haysmacintyre LLP
10 Queen St Place,
London EC4R 1AG